Elevated intestinal fatty acid-binding protein levels as a marker of portal hypertension and gastroesophageal varices in cirrhosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 10 2024
23 10 2024
Historique:
received:
29
02
2024
accepted:
09
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
We measured intestinal fatty acid-binding protein (I-FABP) levels, a useful marker of small intestinal mucosal injury, in patients with cirrhosis to determine their relationship with liver function and complications. This cross-sectional study included 71 patients with cirrhosis admitted for treatment of cirrhotic complications or hepatocellular carcinoma (cohort A) and 104 patients with cirrhosis who received direct-acting antiviral therapy for HCV (cohort B). I-FABP levels, measured by ELISA, were evaluated relative to hepatic reserve and compared with non-invasive scoring systems for diagnostic performance in cirrhotic complications. The median I-FABP level in both cohorts were significantly elevated in patients with reduced hepatic reserve (CTP grade A/BC cohort A, 2.33/3.17 ng/mL, p = 0.032; cohort B, 2.46/3.64 ng/mL, p = 0.008) and complications with gastroesophageal varices (GEV; GEV (-)/(+) cohort A, 1.66/3.67 ng/mL, p < 0.001; cohort B, 2.32/3.36 ng/mL; p = 0.003). Further, multiple logistic regression analysis identified I-FABP as the only factor contributing to GEV presence in both cohorts, which outperformed non-invasive scoring systems for GEV diagnosis (sensitivity 84.6%; specificity 84.2%; sensitivity 69.6%; specificity 63.8%, respectively). In conclusion, elevated small-intestinal mucosal injury in patients with cirrhosis was related to reduced hepatic reserve and GEV presence. I-FABP levels reflect portal hypertension and may be useful in cirrhosis management.
Identifiants
pubmed: 39443545
doi: 10.1038/s41598-024-76040-6
pii: 10.1038/s41598-024-76040-6
doi:
Substances chimiques
Fatty Acid-Binding Proteins
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25003Subventions
Organisme : Grant-in-Aid for Research from the Japan Agency for Medical Research and Development
ID : JP24fk0210113
Informations de copyright
© 2024. The Author(s).
Références
Ginés, P. et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 7, 122–128 (1987).
doi: 10.1002/hep.1840070124
pubmed: 3804191
D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol.44, 217–231 (2006).
doi: 10.1016/j.jhep.2005.10.013
pubmed: 16298014
Smathers, R. L. & Petersen, D. R. The human fatty acid-binding protein family: evolutionary divergences and functions. Hum. Genomics. 5, 170–191 (2011).
doi: 10.1186/1479-7364-5-3-170
pubmed: 21504868
pmcid: 3500171
Li, B., Hao, J., Zeng, J. & Sauter, E. R. SnapShot: FABP functions. Cell. 182, 1066–1066e1 (2020).
doi: 10.1016/j.cell.2020.07.027
pubmed: 32822569
pmcid: 7439965
Gajda, A. M. & Storch, J. Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine. Prostaglandins Leukot. Essent. Fat. Acids. 93, 9–16 (2015).
doi: 10.1016/j.plefa.2014.10.001
Kanda, T. et al. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology. 110, 339–343 (1996).
doi: 10.1053/gast.1996.v110.pm8566578
pubmed: 8566578
Sikora, M. et al. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J. Clin. Med. 8 (2019).
Skinner, C., Thompson, A. J., Thursz, M. R., Marchesi, J. R. & Vergis, N. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therap. Adv. Gastroenterol.13, 1756284820942616 1756284820942616 (2020). (2020).
Kanda, T. et al. Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. J. Gastroenterol.46, 492–500 (2011).
doi: 10.1007/s00535-011-0373-2
pubmed: 21298292
Kodama, M. et al. Endoscopic characterization of the small bowel in patients with portal hypertension evaluated by double balloon endoscopy. J. Gastroenterol.43, 589–596 (2008).
doi: 10.1007/s00535-008-2198-1
pubmed: 18709480
Mekaroonkamol, P., Cohen, R. & Chawla, S. Portal hypertensive enteropathy. World J. Hepatol.7, 127–138 (2015).
doi: 10.4254/wjh.v7.i2.127
pubmed: 25729469
pmcid: 4342596
Aoyama, T. et al. Major predictors of portal hypertensive enteropathy in patients with liver cirrhosis. J. Gastroenterol. Hepatol.30, 124–130 (2015).
doi: 10.1111/jgh.12658
pubmed: 24988903
Otani, I. et al. Clinical significance of small-bowel villous edema in patients with liver cirrhosis: a capsule endoscopy study. J. Gastroenterol. Hepatol.33, 825–830 (2018).
doi: 10.1111/jgh.14016
pubmed: 29023961
Hailman, E. et al. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol.156, 4384–4390 (1996).
doi: 10.4049/jimmunol.156.11.4384
pubmed: 8666811
Albillos, A., Lario, M. & Álvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol.61, 1385–1396 (2014).
doi: 10.1016/j.jhep.2014.08.010
pubmed: 25135860
Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol.72, 558–577 (2020).
doi: 10.1016/j.jhep.2019.10.003
pubmed: 31622696
Pijls, K. E., Jonkers, D. M., Elamin, E. E., Masclee, A. A. & Koek, G. H. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int.33, 1457–1469 (2013).
doi: 10.1111/liv.12271
pubmed: 23879434
Alexopoulou, A., Agiasotelli, D., Vasilieva, L. E. & Dourakis, S. P. Bacterial translocation markers in liver cirrhosis. Ann. Gastroenterol.30, 486–497 (2017).
pubmed: 28845103
pmcid: 5566768
Castéra, L. et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J. Hepatol.50, 59–68 (2009).
doi: 10.1016/j.jhep.2008.08.018
pubmed: 19013661
Sebastiani, G. et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: results of a multicenter, large-scale study. J. Hepatol.53, 630–638 (2010).
doi: 10.1016/j.jhep.2010.04.019
pubmed: 20615567
Wang, L. et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis. PLoS ONE. 12, e0182969 (2017).
doi: 10.1371/journal.pone.0182969
pubmed: 28820885
pmcid: 5562323
Glisic, T. et al. Diagnostic value of non-invasive scoring systems in the prediction of esophageal varices in patients with liver cirrhosis-single Center experience. Med. (Kaunas)58, 158 (2022).
Triantos, C. et al. Endotoxin translocation and gut barrier dysfunction are related to variceal bleeding in patients with liver cirrhosis. Front. Med. (Lausanne). 9, 836306 (2022).
doi: 10.3389/fmed.2022.836306
pubmed: 35308545
Takahashi, Y. et al. Small intestinal edema had the strongest correlation with portal venous pressure amongst capsule endoscopy findings. Digestion. 86, 48–54 (2012).
doi: 10.1159/000338180
pubmed: 22710440
Harki, J. et al. GI ischemia in patients with portal vein thrombosis: a prospective cohort study. Gastrointest. Endosc. 83, 627–636 (2016).
doi: 10.1016/j.gie.2015.07.013
pubmed: 26324386
Okada, K. et al. Intestinal fatty acid-binding protein levels in patients with chronic renal failure. J. Surg. Res.230, 94–100 (2018).
doi: 10.1016/j.jss.2018.04.057
pubmed: 30100046